Clinical data | |
---|---|
Other names | Desmethylenzalutamide; Norenzalutamide |
Drug class | Nonsteroidal antiandrogen |
Pharmacokinetic data | |
Protein binding | 95% [1] |
Elimination half-life | 7.8 days [2] [1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
Chemical and physical data | |
Formula | C20H14F4N4O2S |
Molar mass | 450.41 g·mol−1 |
3D model ( JSmol) | |
| |
|
N-Desmethylenzalutamide is a nonsteroidal antiandrogen (NSAA) and the major metabolite of enzalutamide, an NSAA which is used as a hormonal antineoplastic agent in the treatment of metastatic prostate cancer. [3] [4] [2] It has similar activity to that of enzalutamide and, with enzalutamide therapy, circulates at similar concentrations to those of enzalutamide at steady state. [3] [4] [2] N-Desmethylenzalutamide is formed from enzalutamide in the liver by the cytochrome P450 enzymes CYP2C8 and CYP3A4. [4] It has a longer terminal half-life than enzalutamide (7.8 days versus 5.8 days). [2]